Journey Medical licenses Qbrexza to Maruho for Asia; $19M upfront payment

Journey Medical Corp

Journey receives $19M non-refundable upfront payment from Maruho within 10 days of signing.
Amendment to Japan license removes certain royalties and a $10M milestone but retains up to $45M in milestone payments.
Exclusive license covers 13 Asian markets including South Korea, Taiwan, Hong Kong, and Southeast Asian nations.
Maruho assumes Journey’s payment obligations to Dermira (Eli Lilly) for Territory sales.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.